News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value
Jaguar Health, Inc. announces results of crofelemer trials for rare diseases and adoption of Rights Plan to deter open-market accumulation. FDA meeting expected in Q2 2025 for breast cancer study results -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health, Inc. announces initiation of clinical trial for crofelemer in rare diseases SBS-IF and MVID. First proof-of-concept results expected in H1 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Jaguar Health and Napo Pharmaceuticals extend collaboration with Streeterville related to development of NP-300 drug product candidate for cholera patients, aiming for Tropical Disease Priority Review Voucher from FDA -
-
